Rezolute, Inc. (RZLT) shareholders
Close on Nov 18, 2026Market cap $411.07MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Healthcare Fund, L.P. Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 15,302,186 | 9.90% | 13G (passive) | Dec 11, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (15.00%) | 12,811,876 | 15.00% | 13G (passive) amendment | Jun 30, 2025 |
| Voting Shares Irrevocable Trust Joint filing with Federated Hermes, Inc. (19.99%), Thomas R. Donahue (19.99%) and 2 more | 8,250,274 | 19.99% | 13G (passive) amendment | Dec 31, 2023 |
| James Silverman Joint filing with Opaleye Management Inc. (6.58%), Opaleye, L.P. (6.44%) | 6,300,000 | 6.58% | 13G (passive) amendment | Mar 31, 2026 |
| Dellora Investments LP Joint filing with Kevin Pyun (5.90%), Dellora Investments Master Fund LP (5.10%) | 5,721,834 | 5.90% | 13G (passive) | Aug 5, 2026 |
| Jennison Associates LLC | 5,332,068 | 5.50% | 13G (passive) | Sep 30, 2026 |
| Dmitry Balyasny Joint filing with Balyasny Asset Management L.P. (5.28%), Bam Gp LLC (5.28%) and 2 more | 5,048,421 | 5.28% | 13G (passive) | Mar 31, 2026 |
| Wilmot B. Harkey Joint filing with Nantahala Capital Management, LLC (8.60%), Daniel Mack (8.60%) | 4,966,717 | 8.60% | 13G (passive) amendment | Sep 30, 2024 |
| Opaleye Management Inc. Joint filing with James Silverman (5.30%), Opaleye, L.P. (5.16%) | 4,912,900 | 5.30% | 13G (passive) | Dec 12, 2025 |
| BlackRock, Inc. | 4,881,509 | 5.40% | 13G (passive) | Sep 30, 2025 |
| Raymond Debbane | 4,870,000 | 5.40% | 13G (passive) | Sep 18, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RZLT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 12,990,659 | 13.43% | $67.55M | – | 0.10% |
| Ra Capital Management, L.P. | 9,445,039 | 9.77% | $49.11M | +265,039 | 0.43% |
| BlackRock, Inc. | 7,718,291 | 7.98% | $40.14M | +1,404,788 | 0.00% |
| Opaleye Management Inc. | 6,300,000 | 6.51% | $32.76M | – | 2.97% |
| Balyasny Asset Management L.P. | 4,662,039 | 4.82% | $24.24M | −386,382 | 0.03% |
| Vanguard Capital Management LLC | 3,835,827 | 3.97% | $19.95M | +313,747 | 0.00% |
| Siren, L.L.C. | 3,328,287 | 3.44% | $17.31M | – | 0.35% |
| Jacobs Levy Equity Management, Inc | 2,561,654 | 2.65% | $13.32M | +2,341,247 | 0.05% |
| Jennison Associates LLC | 2,459,308 | 2.54% | $12.79M | −979,573 | 0.01% |
| Geode Capital Management, LLC | 2,170,154 | 2.24% | $11.29M | +205,795 | 0.00% |
| State Street Corp | 1,850,128 | 1.91% | $9.62M | +78,287 | 0.00% |
| D. E. Shaw & Co., Inc. | 1,839,357 | 1.90% | $9.56M | +73,377 | 0.00% |
| Morgan Stanley | 1,618,783 | 1.67% | $8.42M | −1,128,888 | 0.00% |
| Vanguard Portfolio Management LLC | 1,380,746 | 1.43% | $7.18M | −1,601,019 | 0.00% |
| Goldman Sachs Group Inc | 1,316,782 | 1.36% | $6.85M | +714,486 | 0.00% |
| Nuveen, LLC | 1,295,209 | 1.34% | $6.74M | +1,197,523 | 0.00% |
| Kennedy Capital Management LLC | 1,221,678 | 1.26% | $6.35M | −14,420 | 0.11% |
| Blackstone Inc. | 1,082,927 | 1.12% | $5.63M | New | 0.02% |
| Aqr Capital Management LLC | 1,007,962 | 1.04% | $5.24M | +211,266 | 0.00% |
| Affinity Asset Advisors, LLC | 1,000,000 | 1.03% | $5.20M | −547,641 | 0.24% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 144 | 87M | 89.6% | 39 / 60 | 29 / 19 | 13M | 13M |
| Q1 2026 | 125 | 86M | 89.2% | 34 / 37 | 39 / 30 | 22M | 21M |
| Q4 2025 | 122 | 90M | 93.5% | 41 / 44 | 25 / 34 | 42M | 38M |
| Q3 2025 | 116 | 87M | 89.9% | 35 / 39 | 29 / 11 | 18M | 9M |
| Q2 2025 | 92 | 78M | 80.6% | 43 / 33 | 13 / 28 | 39M | 6M |
| Q1 2025 | 77 | 45M | 46.6% | 18 / 31 | 18 / 12 | 11M | 9M |
| Q4 2024 | 71 | 43M | 44.7% | 22 / 23 | 19 / 9 | 9M | 3M |
| Q3 2024 | 59 | 39M | 40.2% | 19 / 20 | 10 / 11 | 4M | 7M |
| Q2 2024 | 52 | 43M | 44.0% | 24 / 18 | 6 / 5 | 16M | 1M |
| Q1 2024 | 33 | 27M | 28.0% | 8 / 9 | 6 / 7 | 3M | 6M |
| Q4 2023 | 32 | 30M | 31.5% | 4 / 11 | 5 / 2 | 9M | 2M |
| Q3 2023 | 30 | 24M | 24.7% | 2 / 4 | 10 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
140 funds held RZLT in Q2 2026, 33% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RZLT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 7,484,000 | 7.74% | $35.32M | 0.72% | Jul 31, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 5,340,860 | 5.52% | $25.21M | 0.89% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,744,647 | 2.84% | $14.27M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,065,733 | 2.14% | $10.74M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,005,732 | 1.04% | $5.23M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 856,711 | 0.89% | $4.04M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 636,980 | 0.66% | $3.31M | 0.02% | Jun 30, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 629,453 | 0.65% | $3.27M | 0.10% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 450,654 | 0.47% | $1.49M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 411,571 | 0.43% | $1.36M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 372,322 | 0.38% | $1.23M | 0.01% | May 31, 2026 |
| Janus Henderson Small Cap Growth Alpha ETF | 320,855 | 0.33% | $1.51M | 0.42% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF | 319,926 | 0.33% | $1.51M | 0.01% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 263,185 | 0.27% | $1.37M | 0.09% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 239,040 | 0.25% | $1.24M | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Nevan C. Elam | CEO, Director | 605,497 | 0.63% | Jul 7, 2026 |
| Daron Evans | CFO | 477,400 | 0.49% | Oct 23, 2026 |
| Sunil Ratilal Karnawat | Chief Commercial Officer | 79,173 | 0.08% | Sep 3, 2026 |
| Brian Kenneth Roberts | Chief Medical Officer | 309,351 | 0.32% | Jul 7, 2026 |
| Wladimir Hogenhuis | Director | 119,675 | 0.12% | Dec 17, 2025 |
| Philippe Fauchet | Director | 55,500 | 0.06% | Nov 21, 2025 |
| Nerissa Kreher | Director | 58,576 | 0.06% | Nov 21, 2025 |
| Gil M. Labrucherie | Director | 109,072 | 0.11% | Nov 21, 2025 |
| Young-Jin Kim | Director | 8,594,336 | 8.89% | Nov 21, 2025 |
| Erik Harris | Director | 21,000 | 0.02% | Nov 21, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Daron Evans CFO | Oct 21, 2026 | Gift | +4,000 | – | – | 11,000 |
| Daron Evans CFO | Oct 21, 2026 | Gift | +4,000 | – | – | 11,000 |
| Daron Evans CFO | Oct 21, 2026 | Gift | −16,000 | – | – | 395,400 |
| Sunil Ratilal Karnawat Chief Commercial Officer | Sep 2, 2026 | Tax withholding | −2,267 | $4.50 | $10.20K | 69,275 |
| Daron Evans CFO | Jul 2, 2026 | Tax withholding | −3,062 | $4.99 | $15.28K | 411,400 |
| Brian Kenneth Roberts Chief Medical Officer | Jul 2, 2026 | Tax withholding | −3,062 | $4.99 | $15.28K | 293,851 |
| Nevan C. Elam CEO, Director | Jul 2, 2026 | Tax withholding | −8,004 | $4.99 | $39.94K | 605,497 |
| Daron Evans CFO | Mar 30, 2026 | Buy | +10,000 | $2.85 | $28.50K | 414,462 |
| Nevan C. Elam CEO, Director | Mar 2, 2026 | Tax withholding | −27,618 | $2.99 | $82.58K | 613,501 |
| Brian Kenneth Roberts Chief Medical Officer | Mar 2, 2026 | Tax withholding | −11,439 | $2.99 | $34.20K | 296,913 |
| Daron Evans CFO | Mar 2, 2026 | Tax withholding | −11,438 | $2.99 | $34.20K | 404,462 |
| Brian Kenneth Roberts Chief Medical Officer | Dec 16, 2025 | Buy | +28,000 | $1.70 | $47.60K | 308,352 |
| Wladimir Hogenhuis Director | Dec 16, 2025 | Buy | +5,650 | $1.69 | $9.55K | 119,675 |
| Daron Evans CFO | Dec 15, 2025 | Buy | +2,500 | $1.79 | $4.48K | 7,000 |
| Daron Evans CFO | Dec 15, 2025 | Buy | +2,500 | $1.79 | $4.48K | 7,000 |
| Daron Evans CFO | Dec 15, 2025 | Buy | +40,000 | $1.77 | $70.80K | 415,900 |
| Sunil Ratilal Karnawat Chief Commercial Officer | Dec 15, 2025 | Buy | +12,000 | $1.62 | $19.44K | 71,442 |
| Sunil Ratilal Karnawat Chief Commercial Officer | Dec 15, 2025 | Buy | +100 | $1.60 | $160 | 71,542 |
| Nevan C. Elam CEO, Director | Dec 15, 2025 | Buy | +32,000 | $1.59 | $50.88K | 641,119 |
| Daron Evans CFO | Dec 9, 2025 | Buy | +10,549 | $5.04 | $53.17K | 131,900 |
| Young-Jin Kim Director | Nov 19, 2025 | Award | +21,000 | – | – | 170,950 |
| Nerissa Kreher Director | Nov 19, 2025 | Award | +21,000 | – | – | 58,576 |
| Wladimir Hogenhuis Director | Nov 19, 2025 | Award | +21,000 | – | – | 114,025 |
| Nevan C. Elam CEO, Director | Nov 19, 2025 | Award | +317,000 | – | – | 609,119 |
| Gil M. Labrucherie Director | Nov 19, 2025 | Award | +21,000 | – | – | 55,500 |
| Brian Kenneth Roberts Chief Medical Officer | Nov 19, 2025 | Award | +123,000 | – | – | 280,352 |
| Philippe Fauchet Director | Nov 19, 2025 | Award | +21,000 | – | – | 55,500 |
| Sunil Ratilal Karnawat Chief Commercial Officer | Nov 19, 2025 | Award | +32,000 | – | – | 59,442 |
| Daron Evans CFO | Nov 19, 2025 | Award | +107,000 | – | – | 375,900 |
| Erik Harris Director | Nov 19, 2025 | Award | +21,000 | – | – | 21,000 |
| Sunil Ratilal Karnawat Chief Commercial Officer | Aug 18, 2025 | Award | +25,000 | – | – | 27,442 |
| Brian Kenneth Roberts Chief Medical Officer | Jun 25, 2025 | Buy | +2,500 | $4.38 | $10.95K | 15,500 |
| Daron Evans CFO | Jun 24, 2025 | Buy | +5,000 | $4.05 | $20.25K | 268,900 |
| Young-Jin Kim Director | Jun 13, 2025 | Buy | +1,230,769 | $3.25 | $4.00M | 8,423,386 |
| Nerissa Kreher Director | Jun 13, 2025 | Buy | +3,076 | $3.25 | $10.00K | 37,576 |
| Wladimir Hogenhuis Director | Jun 10, 2025 | Award | +9,000 | – | – | 93,025 |
| Gil M. Labrucherie Director | Jun 10, 2025 | Award | +9,000 | – | – | 34,500 |
| Nerissa Kreher Director | Jun 10, 2025 | Award | +9,000 | – | – | 34,500 |
| Nevan C. Elam CEO, Director | Jun 10, 2025 | Award | +68,000 | – | – | 292,119 |
| Daron Evans CFO | Jun 10, 2025 | Award | +26,000 | – | – | 263,900 |
| Philippe Fauchet Director | Jun 10, 2025 | Award | +9,000 | – | – | 34,500 |
| Brian Kenneth Roberts Chief Medical Officer | Jun 10, 2025 | Award | +26,000 | – | – | 157,352 |
| Young-Jin Kim Director | Jun 10, 2025 | Award | +9,000 | – | – | 149,950 |
| Wladimir Hogenhuis Director | Mar 31, 2025 | Buy | +6,758 | $2.92 | $19.73K | 84,025 |
| Nevan C. Elam CEO, Director | Mar 27, 2025 | Buy | +12,302 | $2.85 | $35.06K | 224,119 |
| Daron Evans CFO | Mar 26, 2025 | Buy | +10,000 | $2.88 | $28.80K | 23,000 |
| Daron Evans CFO | Mar 26, 2025 | Buy | +10,000 | $2.89 | $28.90K | 237,900 |
| Wladimir Hogenhuis Director | Feb 18, 2025 | Buy | +10,000 | $4.70 | $47.00K | 77,267 |
| Wladimir Hogenhuis Director | Feb 16, 2025 | Award | +25,500 | – | – | 67,267 |
| Gil M. Labrucherie Director | Feb 16, 2025 | Award | +25,500 | – | – | 25,500 |
| Young-Jin Kim Director | Feb 16, 2025 | Award | +25,500 | – | – | 140,950 |
| Nerissa Kreher Director | Feb 16, 2025 | Award | +25,500 | – | – | 25,500 |
| Nevan C. Elam CEO, Director | Feb 16, 2025 | Award | +204,000 | – | – | 211,817 |
| Philippe Fauchet Director | Feb 16, 2025 | Award | +25,500 | – | – | 25,500 |
| Daron Evans CFO | Feb 16, 2025 | Award | +77,000 | – | – | 227,900 |
| Brian Kenneth Roberts Chief Medical Officer | Feb 16, 2025 | Award | +77,000 | – | – | 131,352 |
| Daron Evans CFO | Dec 18, 2024 | Buy | +10,000 | $4.29 | $42.90K | 150,900 |
| Daron Evans CFO | Dec 12, 2024 | Buy | +9,000 | $4.60 | $41.40K | 140,900 |
| Wladimir Hogenhuis Director | Sep 24, 2024 | Buy | +4,259 | $4.70 | $20.02K | 41,767 |
| Young-Jin Kim Director | Jun 25, 2024 | Buy | +1,250,000 | $4.00 | $5.00M | 7,192,617 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Rezolute's stock actually held short. Settlement fails (shares not delivered on time) peaked at 98,801 shares on Aug 26, 2026 over the last 90 days.
See a number that looks wrong?